Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 3,840,000 shares, a growth of 8.2% from the December 15th total of 3,550,000 shares. Based on an average trading volume of 463,300 shares, the short-interest ratio is presently 8.3 days.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ ALDX traded up $0.06 during mid-day trading on Friday, hitting $4.84. 274,810 shares of the stock traded hands, compared to its average volume of 370,307. Aldeyra Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.55. The firm has a 50 day simple moving average of $4.94 and a two-hundred day simple moving average of $4.97. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). Research analysts anticipate that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Aldeyra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. US Bancorp DE bought a new position in Aldeyra Therapeutics during the 3rd quarter worth approximately $30,000. Paloma Partners Management Co acquired a new stake in shares of Aldeyra Therapeutics during the third quarter worth $62,000. The Manufacturers Life Insurance Company raised its stake in Aldeyra Therapeutics by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock worth $72,000 after buying an additional 2,729 shares during the last quarter. King Wealth Management Group lifted its holdings in Aldeyra Therapeutics by 24.5% in the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 2,700 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in Aldeyra Therapeutics by 253.3% during the third quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 10,201 shares during the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.